Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business
AstraZeneca is buying its first vaccine company in a $1.1bn deal that will expand the vaccine and immune therapy business it set up during the Covid pandemic.
Britain’s biggest drugmaker has agreed to take over the Seattle-based company Icosavax, which is developing a potential vaccine for two common respiratory diseases.
More Stories
Russian scientist held in Ice jail charged with smuggling frog embryos into US
Elon Musk shows he still has the White House’s ear on Trump’s Middle East trip
Trump agrees deal for UAE to build largest AI campus outside US